Hematopoietic Stem Cell Core Program Director/Principal Investigator: Gerson, Stanton L. PROJECT SUMMARY (See Instmctions): The Case CCC Hematopoietic Stem Cell Core provides for the procurement, processing, production. Storage, banking, analysis and distribution of cells derived from human blood, bone marrow, and umbilical cords. The Core is composed of two components: 1) A human hematopoietic biorepository and support services to facilitate basic hematopoietic research, and 2) A cellular therapy facility that supports clinical grade cell manufacturing for investigational and standard-of-care therapy. The biorepository procures, processes, banks and distributes human cells from a variety of sources for researchers under an Institutional Review Board (IRB)-approved protocol. This facility obviates the need for Cancer Center members to invest in specialized stem cell reagents and procedures as well as the need to identify and procure blood or bone marrow samples from normal donors and patients with specific hematologic disorders The cellular therapy component of the Core, designated as the Cellular Therapy Service, supports clinical cellular therapy activities from the preclinical phase through clinical trial implementation. While the heaviest use of the Core is by members of the Hematopoietic Disorders Program, the Core has supported work in 6 of the 8 Research Programs of the Cancer Center. In particular, the Core supported work that: investigated the efficacy of novel leukemia therapeutics identified on human AML patient samples as well as determining their myelotoxic effects on normal bone marrow;identified that the combination of fludarabine plus MX represents a potential new clinical targeted therapy;and uses human MSCs to devise a novel model on the trophic and immunomodulatory properties of MSCs that may have important implications in cancer.
The Case Comprehensive Cancer Center is Northeast Ohio's only NCI designated comprehensive cancer center providing bench-to-bedside medical research involving partnerships between basic, clinical and population scientists to speed translation of laboratory discoveries into new prevention/intervention and cancer treatments.
|Zhao, S; Sedwick, D; Wang, Z (2015) Genetic alterations of protein tyrosine phosphatases in human cancers. Oncogene 34:3885-94|
|Dermawan, Josephine Kam Tai; Gurova, Katerina; Pink, John et al. (2014) Quinacrine overcomes resistance to erlotinib by inhibiting FACT, NF-?B, and cell-cycle progression in non-small cell lung cancer. Mol Cancer Ther 13:2203-14|
|Brubaker, Douglas; Difeo, Analisa; Chen, Yanwen et al. (2014) Drug Intervention Response Predictions with PARADIGM (DIRPP) identifies drug resistant cancer cell lines and pathway mechanisms of resistance. Pac Symp Biocomput :125-35|
|Yori, Jennifer L; Lozada, Kristen L; Seachrist, Darcie D et al. (2014) Combined SFK/mTOR inhibition prevents rapamycin-induced feedback activation of AKT and elicits efficient tumor regression. Cancer Res 74:4762-71|
|Dabir, Snehal; Kluge, Amy; McColl, Karen et al. (2014) PIAS3 activates the intrinsic apoptotic pathway in non-small cell lung cancer cells independent of p53 status. Int J Cancer 134:1045-54|
|Zapanta Rinonos, Serendipity; Rai, Urvashi; Vereb, Sydney et al. (2014) Sequential logic of polarity determination during the haploid-to-diploid transition in Saccharomyces cerevisiae. Eukaryot Cell 13:1393-402|
|Sizemore, Gina M; Sizemore, Steven T; Seachrist, Darcie D et al. (2014) GABA(A) receptor pi (GABRP) stimulates basal-like breast cancer cell migration through activation of extracellular-regulated kinase 1/2 (ERK1/2). J Biol Chem 289:24102-13|
|Sossey-Alaoui, Khalid; Pluskota, Elzbieta; Davuluri, Gangarao et al. (2014) Kindlin-3 enhances breast cancer progression and metastasis by activating Twist-mediated angiogenesis. FASEB J 28:2260-71|
|Dotan, Efrat; Devarajan, Karthik; D'Silva, A James et al. (2014) Patterns of use and tolerance of anti-epidermal growth factor receptor antibodies in older adults with metastatic colorectal cancer. Clin Colorectal Cancer 13:192-8|
|Arachiche, Amal; de la Fuente, María; Nieman, Marvin T (2014) Platelet specific promoters are insufficient to express protease activated receptor 1 (PAR1) transgene in mouse platelets. PLoS One 9:e97724|
Showing the most recent 10 out of 975 publications